Revenue: As of FY2025 Q3, the actual value is USD 136.56 M.EPS: As of FY2025 Q3, the actual value is USD -0.14.EBIT: As of FY2025 Q3, the actual value is USD -14.58 M.<h3>Segment Revenue</h3><ul><li>Patient Services: Revenue of $60.2 million for Q3 2025, up from $49.8 million in Q3 2024.</li><li>Dispensary: Revenue of $75.9 million for Q3 2025, up from $48.2 million in Q3 2024.</li><li>Clinical Trials &amp; Other: Revenue of $0.5 million for Q3 2025, down from $1.9 million in Q3 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $16.5 million for Q3 2025, compared to a net loss of $16.1 million in Q3 2024.</li><li>Gross Profit: $18.9 million for Q3 2025, an increase of 31.7% from Q3 2024.</li><li>Adjusted EBITDA: - $3.5 million for Q3 2025, compared to - $8.2 million in Q3 2024.</li></ul><h3>Cash Flow</h3><ul><li>Cash and Cash Equivalents: $27.7 million as of September 30, 2025.</li><li>Free Cash Flow: - $26.9 million for the nine months ended September 30, 2025, compared to - $29.4 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Fee-for-Service Revenue Growth: 13% increase over Q3 2024, driven by organic growth in Florida and Oregon.</li></ul><h3>Outlook / Guidance</h3><ul><li>The Oncology Institute, Inc. updated its full-year 2025 revenue guidance to $495 to $505 million, up from the previous guidance of $460 to $480 million.</li><li>Adjusted EBITDA guidance for 2025 was updated to - $11 to - $13 million, from the previous range of - $8 to - $17 million.</li><li>The company expects Adjusted EBITDA of approximately $0 to $2 million in Q4 2025.</li></ul>

Oncology Institute | 8-K: FY2025 Q3 Revenue: USD 136.56 M